Dr. Jeffrey Jones on the Efficacy of Venetoclax in Treatment for CLL
Jeffrey Jones, MD, discusses small molecule inhibitors of B-cell receptor signaling in chronic lymphocytic leukemia (CLL).
Jeffrey Jones, MD, assistant professor of Internal Medicine, Ohio State University Comprehensive Cancer Center, discusses small molecule inhibitors of B-cell receptor signaling in chronic lymphocytic leukemia (CLL). Jones says both idelalisib and ibrutinib have been highly effective in the majority of relapsed/refractory CLL.
Jones says that while idelalisib and ibrutinib have been effective overall, there is a small group of patients who cannot receieve the treatment. He says that a different option for patients who cannot undergo those treatments are BCL-2 inhibitors like venetoclax. He adds that in a recent study, venetoclax has proven to be effective in the patient population with CLL who cannot receieve idelalisib and ibrutinib due to toxiticies or high-risk genetic features.
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
Lenalidomide Break Possible? Study Shows Hope for MRD-Negative Myeloma
October 7th 2024A new study suggests that patients with multiple myeloma who achieve sustained MRD-negativity for at least three years may be able to discontinue maintenance therapy without compromising their long-term outcomes.
Read More
DREAMM-8 Trial Demonstrates Benefits of Belantamab Mafodotin
October 3rd 2024Belantamab mafodotin plus pomalidomide and dexamethasone showed significant progression-free survival benefits and maintained quality of life in patients with relapsed/refractory multiple myeloma, as demonstrated in the DREAMM-8 trial.
Read More
